Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has issued an announcement.
Telix Pharmaceuticals Limited has announced the release of 2,427,636 ordinary shares from voluntary escrow, which were initially issued to QSAM Biosciences Inc. shareholders as part of Telix’s acquisition of QSAM. This release, scheduled for May 3, 2025, is in accordance with ASX Listing Rule 3.10A and marks a significant step in the integration process following the acquisition. The release of these shares is expected to impact Telix’s market operations by potentially increasing the liquidity of its shares and enhancing shareholder value.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company that specializes in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and related medical technologies. The company is headquartered in Melbourne, Australia, and operates internationally in the United States, Brazil, Canada, Europe, and Japan. Telix focuses on addressing significant unmet medical needs in oncology and rare diseases with a portfolio of clinical and commercial stage products.
YTD Price Performance: 13.10%
Average Trading Volume: 5,007
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.44B
See more insights into TLX stock on TipRanks’ Stock Analysis page.